International Journal of Clinical Research

Objective: To observe the effect of phentolamine combined with kalosulfonate in the treatment of bronchiectasis with hemoptysis. Methods: 200 patients with bronchiectasis and hemoptysis received from November 2019 to November 2021 were included in the study. They were randomly divided into experimental group and reference group by double-blind method, with 100 cases in each group. The patients in both groups received basic treatment. In terms of drug treatment, the reference group was treated with carbosulfan sodium, and the experimental group was treated with phentolamine combined with carbosulfan sodium. The volume of hemoptysis, the length of hemoptysis disappearance, pulmonary function indexes before and after treatment (FEV1, FVC, fev1/fvc) and adverse reaction generation index were compared between the two groups. Results: the amount of hemoptysis in the experimental group was lower than that in the reference group, and the length of hemoptysis disappearance was shorter than that in the reference group, with statistical difference (P < 0.05); Before treatment, there was no statistical difference in pulmonary function indexes between the two groups (P > 0.05). After treatment, the pulmonary function indexes of the two groups were significantly improved, in which FEV1, FVC and fev1/fvc in the experimental group were higher than those in the reference group, with statistical difference (P < 0.05); There was no significant difference in the adverse reaction index between the two groups (P > 0.05). Conclusion: phentolamine combined with kalosulfonate has a significant effect in the treatment of bronchiectasis with hemoptysis, which is beneficial to accelerate the disappearance of hemoptysis symptoms, help the recovery of lung function, and do not increase the risk of adverse reactions.

Phentolamine; Sodium Carbazone Sulfonate; Bronchiectasia; Hemoptysis; Pulmonary Function